Clinical trial
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
NCT05873686
Study timeline
Study start (actual)2023-10-26Date precision: day
Registry last updated2026-09-30
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Advanced Solid Tumorunresolved
NSCLC (Non-small Cell Lung Cancer)unresolved
Renal Cancerunresolved
Mesotheliomaunresolved
Non-Small Cell Squamous Lung Cancerunresolved
Non-small Cell Lung Adenocarcinomaunresolved
Interventions
NXP900DRUG
Sponsors & collaborators
Nuvectis Pharma, Inc.lead sponsor
Mapped research locations
HoustonTexas, United States2New YorkNew York, United States1ChicagoIllinois, United States1LondonUnited Kingdom1ClevelandOhio, United States1PortlandOregon, United States1PhoenixArizona, United States1JacksonvilleFlorida, United States1DenverColorado, United States1RochesterMinnesota, United States1La JollaCalifornia, United States1FairfaxVirginia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05873686 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.